首页 | 本学科首页   官方微博 | 高级检索  
     

不同疗程的孟鲁司特钠口服治疗对呼吸道合胞病毒毛细支气管炎后反复喘息及哮喘的预防作用
引用本文:刘兴芬. 不同疗程的孟鲁司特钠口服治疗对呼吸道合胞病毒毛细支气管炎后反复喘息及哮喘的预防作用[J]. 中国医药指南, 2013, 0(2): 24-25
作者姓名:刘兴芬
作者单位:隆昌县妇幼保健院
摘    要:目的探讨不同疗程的孟鲁司特钠口服治疗对预防引起哮喘和喘息的呼吸道合胞病毒毛细支气管炎。方法 2010年1月至2012年1月治疗的265例呼吸道合胞病毒毛细支气管炎患者,从中随机分配分为3组,分别是甲、乙、丙三组。当中为治疗组的是甲、乙两组,甲组77例,乙组82例;丙组66例,为对照组。急性期症状控制后,甲组69例给予孟鲁司特钠口服,6个月以下2.5mg/d,6个月以上4mg/d,每晚服用1次,连服半年;乙组82例同甲组的用药方法和剂量相同,但只连服3个月;丙组66例,没有任何治疗。疗程结束后每1~3个月随访1次,持续2年,观察喘息复发情况。结果治疗组合计与对照组比较,χ2=13.64,P<0.01;甲组与丙组比较,χ2=10.48,P<0.01;乙组与丙组比较,χ2=6.10,P<0.05;甲组与乙组比较,χ2=1.10,P>0.05。治疗组与对照组相比差异很显著。但无显著差异的是经过校正χ2检验甲、乙两组之间的哮喘发生率。结论支气管炎急性期症状控制后继续给予孟鲁司特口服治疗,可降低RSV毛细支气管炎后哮喘的发生率,可继续给予孟鲁司特口服治疗3个月。

关 键 词:孟鲁司特钠  毛细支气管炎  预防

Different Course of Montelukast Sodium, Oral Treatment of Respiratory Syncytial Virus Capillary Bronchitis and Asthma after Wheeze and Prevention Role
LIU Xing-fen. Different Course of Montelukast Sodium, Oral Treatment of Respiratory Syncytial Virus Capillary Bronchitis and Asthma after Wheeze and Prevention Role[J]. Guide of China Medicine, 2013, 0(2): 24-25
Authors:LIU Xing-fen
Affiliation:LIU Xing-fen(Longchang Maternity and Child Care Centers,Neijiang 642150,China)
Abstract:Objective To explore different course of Montelukast sodium,oral treatment of respiratory syncytial virus capillary bronchitis and asthma after wheeze and prevention role.Methods 2009-2012 to 217 cases were RSV capillary bronchitises trouble,with simple random sampling is divided into a,b,and c three groups.Among them the first 69 cases,and revealed the 75 cases,the two groups for the treatment group;C group 73 examples,as control group.After the acute phase symptom control,the first 69 cases Montelukast sodium,give sodium by,under 6 months 2.5 mg/d,6 months above 4 mg/d,take one time every night,and even served six months;75 cases were revealed the dosage and with the first method,but even served three months;C group 73 examples,and not to any intervention.After the course every one to three months follow-up 1,the last two years,panting observation recurrence.Results The treatment combination plan compared with controls,χ2= 13.64,P0.01;The first group compared with c,χ2=10.48,P 0.01;Junior group b and c group compared,χ2=6.10,P 0.05;The first paper and comparison,χ2=1.10,P 0.05.The treatment group and control group is significantly.But amour,between the incidence of asthma and revealed the by correction χ2 inspection no significant differences.Conclusion Bronchitis acute period after symptom control,continue to give Montelukast sodium,oral therapy,can reduce RSV capillary bronchitis after the incidence of asthma,can continue to give oral treatment Montelukast sodium,3 months.
Keywords:Montelukast sodium  Capillary bronchitis  Prevention
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号